Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

Albuquerque Acupuncture and Integrative Medicine is a local clinic specializing in treating complex chronic illnesses such as ...

AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN).

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Your nervous system is a key force behind so many important bodily functions. But when your peripheral nerves—those found outside of the brain and spinal cord—are damaged, it can cause pain and ...

NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

No statistical difference was reported in time to onset of CIPN between the 2 groups. Additionally, 75% of the patients undergoing treatment with gemcitabine plus albumin-bound paclitaxel did not ...